

John E J Rasko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605848/publications.pdf>

Version: 2024-02-01

213
papers

14,926
citations

26630

56
h-index

20961

115
g-index

222
all docs

222
docs citations

222
times ranked

18423
citing authors

#	ARTICLE	IF	CITATIONS
1	Unique protein interaction networks define the chromatin remodelling module of the NuRD complex. <i>FEBS Journal</i> , 2022, 289, 199-214.	4.7	13
2	Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience. <i>Cytotherapy</i> , 2022, 24, 45-48.	0.7	2
3	Dynamic intron retention modulates gene expression in the monocytic differentiation pathway. <i>Immunology</i> , 2022, 165, 274-286.	4.4	7
4	Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1671.	4.1	18
5	The next wave of cellular immunotherapies in pancreatic cancer. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 561-576.	4.4	34
6	Mapping oncogenic protein interactions for precision medicine. <i>International Journal of Cancer</i> , 2022, , .	5.1	6
7	Sprouty and Spred temporally regulate ERK1/2-signaling to suppress TGF β 2-induced lens EMT. <i>Experimental Eye Research</i> , 2022, 219, 109070.	2.6	3
8	20 Years of Legislation - How Australia Has Responded to the Challenge of Regulating Genetically Modified Organisms in the Clinic. <i>Frontiers in Medicine</i> , 2022, 9, .	2.6	2
9	Clinical gene technology in Australia: building on solid foundations. <i>Medical Journal of Australia</i> , 2022, 217, 65-70.	1.7	2
10	Locoregional delivery of CAR-T cells in the clinic. <i>Pharmacological Research</i> , 2022, 182, 106329.	7.1	9
11	Holding on to Junk Bonds: Intron Retention in Cancer and Therapy. <i>Cancer Research</i> , 2021, 81, 779-789.	0.9	19
12	Journey to the Center of the Cell: Tracing the Path of AAV Transduction. <i>Trends in Molecular Medicine</i> , 2021, 27, 172-184.	6.7	42
13	<i>Ctcf</i> haploinsufficiency mediates intron retention in a tissue-specific manner. <i>RNA Biology</i> , 2021, 18, 93-103.	3.1	12
14	Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. <i>Biomarker Research</i> , 2021, 9, 11.	6.8	46
15	CTCF as a regulator of alternative splicing: new tricks for an old player. <i>Nucleic Acids Research</i> , 2021, 49, 7825-7838.	14.5	31
16	Hitting the Bull's-Eye: Mesothelin's Role as a Biomarker and Therapeutic Target for Malignant Pleural Mesothelioma. <i>Cancers</i> , 2021, 13, 3932.	3.7	16
17	Splice and Dice: Intronic microRNAs, Splicing and Cancer. <i>Biomedicines</i> , 2021, 9, 1268.	3.2	8
18	Computational Methods for Intron Retention Identification and Quantification. , 2021, , 63-74.		0

#	ARTICLE	IF	CITATIONS
19	Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 761616.	4.8	37
20	Structure–function relationships explain CTCF zinc finger mutation phenotypes in cancer. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7519-7536.	5.4	12
21	The Fusion of CLEC12A and MIR223HG Arises from a trans-Splicing Event in Normal and Transformed Human Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12178.	4.1	4
22	Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A. <i>New England Journal of Medicine</i> , 2021, 385, 1961-1973.	27.0	127
23	Follow-up of More Than 5 Years in a Cohort of Patients with Hemophilia B Treated with Fidanacogene Elaparvovec Adeno-Associated Virus Gene Therapy. <i>Blood</i> , 2021, 138, 3975-3975.	1.4	13
24	A warm welcome to Paris – Virtual!. <i>Cytotherapy</i> , 2020, 22, S1-S2.	0.7	0
25	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 134.	17.1	84
26	Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. <i>Nature Medicine</i> , 2020, 26, 1720-1725.	30.7	187
27	Global citizen deliberation on genome editing. <i>Science</i> , 2020, 369, 1435-1437.	12.6	47
28	Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. <i>Cancers</i> , 2020, 12, 3738.	3.7	10
29	Surveying brain tumor heterogeneity by single-cell RNA-sequencing of multi-sector biopsies. <i>National Science Review</i> , 2020, 7, 1306-1318.	9.5	84
30	The COVID-19 outbreak: a snapshot from down under. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 433-436.	2.4	2
31	Camrelizumab Plus Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: A Single-Arm, Open-Label, Phase II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 4521-4530.	7.0	15
32	Advances in targeted therapy for malignant lymphoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 15.	17.1	66
33	Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B. <i>Molecular Therapy</i> , 2020, 28, 2073-2082.	8.2	123
34	Endothelial E-selectin inhibition improves acute myeloid leukaemia therapy by disrupting vascular niche-mediated chemoresistance. <i>Nature Communications</i> , 2020, 11, 2042.	12.8	99
35	Macrophage development and activation involve coordinated intron retention in key inflammatory regulators. <i>Nucleic Acids Research</i> , 2020, 48, 6513-6529.	14.5	45
36	Exosomal lncRNAs and cancer: connecting the missing links. <i>Bioinformatics</i> , 2019, 35, 352-360.	4.1	51

#	ARTICLE	IF	CITATIONS
37	EGF-activated PI3K/Akt signalling coordinates leucine uptake by regulating LAT3 expression in prostate cancer. <i>Cell Communication and Signaling</i> , 2019, 17, 83.	6.5	20
38	Stem Cell Businesses and Right to Try Laws. <i>Cell Stem Cell</i> , 2019, 25, 304-305.	11.1	5
39	Cell and gene therapy manufacturing capabilities in Australia and New Zealand. <i>Cytotherapy</i> , 2019, 21, 1258-1273.	0.7	9
40	The changing paradigm of intron retention: regulation, ramifications and recipes. <i>Nucleic Acids Research</i> , 2019, 47, 11497-11513.	14.5	90
41	The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1366.	2.8	50
42	DNA methylation/hydroxymethylation regulate gene expression and alternative splicing during terminal granulopoiesis. <i>Epigenomics</i> , 2019, 11, 95-109.	2.1	18
43	Spred negatively regulates lens growth by modulating epithelial cell proliferation and fiber differentiation. <i>Experimental Eye Research</i> , 2019, 178, 160-175.	2.6	10
44	Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year. <i>Blood</i> , 2019, 134, 3347-3347.	1.4	19
45	No Vacillation on HPV Vaccination. <i>Cell</i> , 2018, 172, 1163-1167.	28.9	20
46	Negative regulation of lens fiber cell differentiation by RTK antagonists Spry and Spred. <i>Experimental Eye Research</i> , 2018, 170, 148-159.	2.6	10
47	Gene Therapy in Patients with Transfusion-Dependent β^2 -Thalassemia. <i>New England Journal of Medicine</i> , 2018, 378, 1479-1493.	27.0	525
48	An intriguing, new planarian species from Tasmania, with a discussion on protandry in triclad flatworms (Platyhelminthes, Tricladida). <i>Acta Zoologica</i> , 2018, 99, 404-414.	0.8	0
49	We skip to work: alternative splicing in normal and malignant myelopoiesis. <i>Leukemia</i> , 2018, 32, 1081-1093.	7.2	33
50	Diversity of transcripts emanating from protein-coding genes. <i>Seminars in Cell and Developmental Biology</i> , 2018, 75, 1-2.	5.0	0
51	Challenges in defining the role of intron retention in normal biology and disease. <i>Seminars in Cell and Developmental Biology</i> , 2018, 75, 40-49.	5.0	51
52	CTCF Expression is Essential for Somatic Cell Viability and Protection Against Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3832.	4.1	17
53	Cell, tissue and gene products with marketing authorization in 2018 worldwide. <i>Cytotherapy</i> , 2018, 20, 1401-1413.	0.7	87
54	Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy. <i>Biochemical and Biophysical Research Communications</i> , 2018, 503, 1861-1867.	2.1	6

#	ARTICLE	IF	CITATIONS
55	Guidelines for whole genome bisulphite sequencing of intact and FFPE DNA on the Illumina HiSeq X Ten. <i>Epigenetics and Chromatin</i> , 2018, 11, 24.	3.9	38
56	Identifying microRNA determinants of human myelopoiesis. <i>Scientific Reports</i> , 2018, 8, 7264.	3.3	14
57	A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD. <i>Blood</i> , 2018, 132, 4562-4562.	1.4	6
58	Nuclear microRNAs in normal hemopoiesis and cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 8.	17.0	33
59	Genetic alterations of m6A regulators predict poorer survival in acute myeloid leukemia. <i>Journal of Hematology and Oncology</i> , 2017, 10, 39.	17.0	215
60	Intron retention is regulated by altered MeCP2-mediated splicing factor recruitment. <i>Nature Communications</i> , 2017, 8, 15134.	12.8	92
61	Computational and Experimental Identification of Tissue-Specific MicroRNA Targets. <i>Methods in Molecular Biology</i> , 2017, 1580, 127-147.	0.9	6
62	The antiproliferative ELF2 isoform, ELF2B, induces apoptosis in vitro and perturbs early lymphocytic development in vivo. <i>Journal of Hematology and Oncology</i> , 2017, 10, 75.	17.0	16
63	CTCF genetic alterations in endometrial carcinoma are pro-tumorigenic. <i>Oncogene</i> , 2017, 36, 4100-4110.	5.9	50
64	Marketing of unproven stem cell-based interventions: A call to action. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	147
65	ASCT2 regulates glutamine uptake and cell growth in endometrial carcinoma. <i>Oncogenesis</i> , 2017, 6, e367-e367.	4.9	57
66	Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant. <i>New England Journal of Medicine</i> , 2017, 377, 2215-2227.	27.0	549
67	IRFinder: assessing the impact of intron retention on mammalian gene expression. <i>Genome Biology</i> , 2017, 18, 51.	8.8	203
68	First Approved Kinase Inhibitor for AML. <i>Cell</i> , 2017, 171, 981.	28.9	10
69	Show drugs work before selling them. <i>Nature</i> , 2017, 543, 174-175.	27.8	10
70	Implicit hype? Representations of platelet rich plasma in the news media. <i>PLoS ONE</i> , 2017, 12, e0182496.	2.5	46
71	Intron retention enhances gene regulatory complexity in vertebrates. <i>Genome Biology</i> , 2017, 18, 216.	8.8	79
72	A dynamic intron retention program in the mammalian megakaryocyte and erythrocyte lineages. <i>Blood</i> , 2016, 127, e24-e34.	1.4	94

#	ARTICLE	IF	CITATIONS
73	Part 2: Making the "unproven" "proven". Cytotherapy, 2016, 18, 120-123.	0.7	6
74	Experimental approaches to studying the nature and impact of splicing variation in zebrafish. Methods in Cell Biology, 2016, 135, 259-288.	1.1	2
75	LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma. International Journal of Cancer, 2016, 139, 2529-2539.	5.1	36
76	Global Distribution of Businesses Marketing Stem Cell-Based Interventions. Cell Stem Cell, 2016, 19, 158-162.	11.1	126
77	Intron retention in mRNA: No longer nonsense. BioEssays, 2016, 38, 41-49.	2.5	163
78	Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471.	0.6	7
79	RBM3 regulates temperature sensitive miR-142 ^{5p} and miR-143 (thermomiRs), which target immune genes and control fever. Nucleic Acids Research, 2016, 44, 2888-2897.	14.5	50
80	ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene, 2016, 35, 3201-3208.	5.9	430
81	PtdIns(3,4,5)P3-dependent Rac Exchanger 1 (PREX1) Rac-Guanine Nucleotide Exchange Factor (GEF) Activity Promotes Breast Cancer Cell Proliferation and Tumor Growth via Activation of Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Signaling. Journal of Biological Chemistry, 2016, 291, 17258-17270.	3.4	18
82	Lentiglobin Gene Therapy for Transfusion-Dependent β^2 -Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study. Blood, 2016, 128, 1175-1175.	1.4	17
83	Science, ethics and communication remain essential for the success of cell-based therapies. Brain Circulation, 2016, 2, 146.	1.8	7
84	Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. Journal of Pathology, 2015, 236, 278-289.	4.5	275
85	Comparative analyses of CTCF and BORIS occupancies uncover two distinct classes of CTCF binding genomic regions. Genome Biology, 2015, 16, 161.	8.8	83
86	Positioning a Scientific Community on Unproven Cellular Therapies: The 2015 International Society for Cellular Therapy Perspective. Cytotherapy, 2015, 17, 1663-1666.	0.7	44
87	A Dynamic Intron Retention Program in the Mammalian Megakaryocyte and Erythrocyte Lineages. Blood, 2015, 126, 2380-2380.	1.4	1
88	Epigenetic modifications of splicing factor genes in myelodysplastic syndromes and acute myeloid leukemia. Cancer Science, 2014, 105, 1457-1463.	3.9	21
89	Targeting glutamine transport to suppress melanoma cell growth. International Journal of Cancer, 2014, 135, 1060-1071.	5.1	179
90	Small RNA changes en route to distinct cellular states of induced pluripotency. Nature Communications, 2014, 5, 5522.	12.8	54

#	ARTICLE	IF	CITATIONS
91	Genome-wide characterization of the routes to pluripotency. <i>Nature</i> , 2014, 516, 198-206.	27.8	187
92	Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for Human Blood and Blood Components, Human Tissues and Human Cellular Therapy Products. <i>Pathology</i> , 2014, 46, 177-183.	0.6	5
93	CTCF and BORIS in genome regulation and cancer. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 8-15.	3.3	44
94	Clinical potential of gene therapy: towards meeting the demand. <i>Internal Medicine Journal</i> , 2014, 44, 224-233.	0.8	10
95	Monoterpene Glycoside ESK246 from <i>Pittosporum</i> Targets LAT3 Amino Acid Transport and Prostate Cancer Cell Growth. <i>ACS Chemical Biology</i> , 2014, 9, 1369-1376.	3.4	35
96	Identification of nuclear-enriched miRNAs during mouse granulopoiesis. <i>Journal of Hematology and Oncology</i> , 2014, 7, 42.	17.0	29
97	Inhibition of glutamine uptake regulates mTORC1, glutamine metabolism and cell growth in prostate cancer. <i>Cancer & Metabolism</i> , 2014, 2, P27.	5.0	0
98	Circulating tumour cells and circulating free nucleic acid as prognostic and predictive biomarkers in colorectal cancer. <i>Cancer Letters</i> , 2014, 346, 24-33.	7.2	54
99	Refining microRNA target predictions: Sorting the wheat from the chaff. <i>Biochemical and Biophysical Research Communications</i> , 2014, 445, 780-784.	2.1	31
100	Innovations: advances in cellular therapies relating to haematological conditions. <i>Pathology</i> , 2014, 46, S31.	0.6	0
101	NMR q-space analysis of canonical shapes of human erythrocytes: stomatocytes, discocytes, spherocytes and echinocytes. <i>European Biophysics Journal</i> , 2013, 42, 3-16.	2.2	6
102	Orchestrated Intron Retention Regulates Normal Granulocyte Differentiation. <i>Cell</i> , 2013, 154, 583-595.	28.9	408
103	miREval 2.0: a web tool for simple microRNA prediction in genome sequences. <i>Bioinformatics</i> , 2013, 29, 3225-3226.	4.1	50
104	MicroRNA Target Prediction and Validation. <i>Advances in Experimental Medicine and Biology</i> , 2013, 774, 39-53.	1.6	54
105	Nichotherapy for stem cells: There goes the neighborhood. <i>BioEssays</i> , 2013, 35, 183-190.	2.5	14
106	MicroRNAs in myeloid malignancies. <i>British Journal of Haematology</i> , 2013, 162, 162-176.	2.5	39
107	The cancer testis antigen BORIS phenocopies the tumor suppressor CTCF in normal and neoplastic cells. <i>International Journal of Cancer</i> , 2013, 133, 1603-1613.	5.1	48
108	Targeting Amino Acid Transport in Metastatic Castration-Resistant Prostate Cancer: Effects on Cell Cycle, Cell Growth, and Tumor Development. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1463-1473.	6.3	147

#	ARTICLE	IF	CITATIONS
109	Defining and providing robust controls for microRNA prediction. <i>Bioinformatics</i> , 2012, 28, 1058-1061.	4.1	31
110	New developments in cell and gene therapy. <i>Pathology</i> , 2012, 44, S33-S34.	0.6	0
111	Integrated miRNA Expression Analysis and Target Prediction. <i>Methods in Molecular Biology</i> , 2012, 822, 289-293.	0.9	3
112	Androgen receptor and nutrient signaling pathways coordinate increased amino acid transport in prostate cancer progression. <i>BMC Proceedings</i> , 2012, 6, .	1.6	1
113	Intron Retention Coupled with Nonsense-Mediated Decay Determines Protein Expression and Nuclear Morphology in Granulopoiesis. <i>Blood</i> , 2012, 120, 112-112.	1.4	9
114	Disambiguating epigenetics. <i>Pathology</i> , 2011, 43, S35-S36.	0.6	0
115	OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. <i>Haematologica</i> , 2011, 96, 213-220.	3.5	13
116	Will Cell Reprogramming Resolve the Embryonic Stem Cell Controversy? A Narrative Review. <i>Annals of Internal Medicine</i> , 2011, 155, 114.	3.9	18
117	Promises and Challenges of Stem Cell Research for Regenerative Medicine. <i>Annals of Internal Medicine</i> , 2011, 155, 706.	3.9	18
118	Mobilisation strategies for normal and malignant cells. <i>Pathology</i> , 2011, 43, 547-565.	0.6	8
119	Future Path: frontiers of molecular and cellular pathology. <i>Pathology</i> , 2011, 43, 523-524.	0.6	2
120	Cellular therapy in the Asia-Pacific region. A guide for the future pathologist. <i>Pathology</i> , 2011, 43, 616-626.	0.6	3
121	Gene therapy: therapeutic applications and relevance to pathology. <i>Pathology</i> , 2011, 43, 642-656.	0.6	14
122	How we mobilize haemopoietic stem cells. <i>Internal Medicine Journal</i> , 2011, 41, 588-594.	0.8	8
123	Impaired Nutrient Signaling and Body Weight Control in a Na ⁺ Neutral Amino Acid Cotransporter (Slc6a19)-deficient Mouse. <i>Journal of Biological Chemistry</i> , 2011, 286, 26638-26651.	3.4	76
124	Identification of P-Rex1 as a Novel Rac1-Guanine Nucleotide Exchange Factor (GEF) That Promotes Actin Remodeling and GLUT4 Protein Trafficking in Adipocytes. <i>Journal of Biological Chemistry</i> , 2011, 286, 43229-43240.	3.4	53
125	Androgen Receptor and Nutrient Signaling Pathways Coordinate the Demand for Increased Amino Acid Transport during Prostate Cancer Progression. <i>Cancer Research</i> , 2011, 71, 7525-7536.	0.9	145
126	Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. <i>Journal of Clinical Investigation</i> , 2011, 121, 446-453.	8.2	117

#	ARTICLE	IF	CITATIONS
127	Renal imino acid and glycine transport system ontogeny and involvement in developmental iminoglycinuria. <i>Biochemical Journal</i> , 2010, 428, 397-407.	3.7	56
128	Loss of Solute Carriers in T Cell-Mediated Rejection in Mouse and Human Kidneys: An Active Epithelial Injury-Repair Response. <i>American Journal of Transplantation</i> , 2010, 10, 2241-2251.	4.7	32
129	Concise review: Nanoparticles and cellular carriers-allies in cancer imaging and cellular gene therapy?. <i>Stem Cells</i> , 2010, 28, 1686-1702.	3.2	56
130	A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. <i>Journal of Internal Medicine</i> , 2010, 268, 286-295.	6.0	86
131	Nuclear-localized tiny RNAs are associated with transcription initiation and splice sites in metazoans. <i>Nature Structural and Molecular Biology</i> , 2010, 17, 1030-1034.	8.2	146
132	Substrate elasticity provides mechanical signals for the expansion of hemopoietic stem and progenitor cells. <i>Nature Biotechnology</i> , 2010, 28, 1123-1128.	17.5	244
133	A gene therapy renaissance?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 848-850.	2.8	2
134	Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 22231-22236.	7.1	249
135	Autologous Transplantation of Endothelial Progenitor Cells Genetically Modified by Adeno-Associated Viral Vector Delivering Insulin-Like Growth Factor-1 Gene After Myocardial Infarction. <i>Human Gene Therapy</i> , 2010, 21, 1327-1334.	2.7	33
136	Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia. <i>Haematologica</i> , 2010, 95, 1325-1333.	3.5	113
137	mimiRNA: a microRNA expression profiler and classification resource designed to identify functional correlations between microRNAs and their targets. <i>Bioinformatics</i> , 2010, 26, 223-227.	4.1	75
138	Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo. <i>Molecular Cancer</i> , 2010, 9, 299.	19.2	77
139	A changing time: the International Society for Cellular Therapy embraces its industry members. <i>Cytotherapy</i> , 2010, 12, 853-856.	0.7	1
140	Cell therapy medical tourism: Time for action. <i>Cytotherapy</i> , 2010, 12, 965-968.	0.7	42
141	Gene Therapy for Hemophilia: Clinical Trials and Technical Tribulations. <i>Seminars in Thrombosis and Hemostasis</i> , 2009, 35, 081-092.	2.7	38
142	Conserved Expression Patterns Predict microRNA Targets. <i>PLoS Computational Biology</i> , 2009, 5, e1000513.	3.2	49
143	Predicting microRNA targets and functions: traps for the unwary. <i>Nature Methods</i> , 2009, 6, 397-398.	19.0	168
144	Throwing the baby out with the bathwater: microRNAs have critical roles in health and disease. <i>Pathology</i> , 2009, 41, 203.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Developing strategies for detection of gene doping. <i>Journal of Gene Medicine</i> , 2008, 10, 3-20.	2.8	53
146	Further evidence for allelic heterogeneity in Hartnup disorder. <i>Human Mutation</i> , 2008, 29, 1217-1221.	2.5	30
147	Improved Granulocyte Colony-Stimulating Factor Mobilization of Hemopoietic Progenitors Using Cytokine Combinations in Primates. <i>Stem Cells</i> , 2008, 26, 2974-2980.	3.2	6
148	A protein complex in the brushboarder membrane explains a Hartnup disorder allele. <i>FASEB Journal</i> , 2008, 22, 2880-2887.	0.5	193
149	MicroRNA in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2008, 359, 653-654.	27.0	2
150	Whither Prometheus' Liver? Greek Myth and the Science of Regeneration. <i>Annals of Internal Medicine</i> , 2008, 149, 421.	3.9	28
151	Tell haematologists there's been no progress in CML and see yelli!. <i>Pathology</i> , 2008, 40, 229-230.	0.6	0
152	Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. <i>Journal of Clinical Investigation</i> , 2008, 118, 3881-3892.	8.2	101
153	Potential Use of Gene Transfer in Athletic Performance Enhancement. <i>Molecular Therapy</i> , 2007, 15, 1751-1766.	8.2	65
154	Regulation of Fc γ 3R-stimulated phagocytosis by the 72-kDa inositol polyphosphate 5-phosphatase: SHIP1, but not the 72-kDa 5-phosphatase, regulates complement receptor 3-mediated phagocytosis by differential recruitment of these 5-phosphatases to the phagocytic cup. <i>Blood</i> , 2007, 110, 4480-4491.	1.4	52
155	Autofluorescent Proteins for Flow Cytometry. , 2007, 411, 99-110.		1
156	Cell and gene therapy in Australia. <i>Cytotherapy</i> , 2007, 9, 209-221.	0.7	3
157	Distribution of human endogenous retrovirus type W receptor in normal human villous placenta. <i>Pathology</i> , 2007, 39, 406-412.	0.6	28
158	Profound thrombocytopenia related to G-CSF. <i>American Journal of Hematology</i> , 2007, 82, 229-230.	4.1	21
159	Specific adeno-associated virus serotypes facilitate efficient gene transfer into human and non-human primate mesenchymal stromal cells. <i>Journal of Gene Medicine</i> , 2007, 9, 22-32.	2.8	14
160	CD8+ T-cell responses to adeno-associated virus capsid in humans. <i>Nature Medicine</i> , 2007, 13, 419-422.	30.7	629
161	Duration of ERK1/2 phosphorylation induced by FGF or ocular media determines lens cell fate. <i>Differentiation</i> , 2007, 75, 662-668.	1.9	49
162	Persistence of the Common Hartnup Disease D173N Allele in Populations of European Origin. <i>Annals of Human Genetics</i> , 2007, 71, 755-761.	0.8	14

#	ARTICLE	IF	CITATIONS
163	Aqueous humour- and growth factor-induced lens cell proliferation is dependent on MAPK/ERK1/2 and Akt/PI3-K signalling. <i>Experimental Eye Research</i> , 2006, 83, 667-678.	2.6	53
164	Molecular insights from a novel cardiac troponin I mouse model of familial hypertrophic cardiomyopathy. <i>Journal of Molecular and Cellular Cardiology</i> , 2006, 41, 623-632.	1.9	33
165	Induced dystrophin exon skipping in human muscle explants. <i>Neuromuscular Disorders</i> , 2006, 16, 583-590.	0.6	63
166	Bill to ban reproduction of inmates with cancer proposed in New South Wales. <i>Medical Journal of Australia</i> , 2006, 185, 575-576.	1.7	1
167	Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. <i>Nature Medicine</i> , 2006, 12, 342-347.	30.7	1,865
168	The molecular basis of neutral aminoacidurias. <i>Pflügers Archiv European Journal of Physiology</i> , 2006, 451, 511-517.	2.8	54
169	The Use of Retroviral Vectors for Gene Transfer into Hematopoietic Stem Cells. <i>Methods in Enzymology</i> , 2006, 420, 82-100.	1.0	1
170	Phosphatidylinositol 3-Phosphate [PtdIns(3)P] Is Generated at the Plasma Membrane by an Inositol Polyphosphate 5-Phosphatase: Endogenous PtdIns(3)P Can Promote GLUT4 Translocation to the Plasma Membrane. <i>Molecular and Cellular Biology</i> , 2006, 26, 6065-6081.	2.3	56
171	AAV-2 Capsid-Specific CD8+ T Cells Limit the Duration of Gene Therapy in Humans and Cross-React with AAV-8 Capsid. <i>Blood</i> , 2006, 108, 455-455.	1.4	2
172	Damage to incisors after nonmyeloablative total body irradiation may complicate NOD/SCID models of hemopoietic stem cell transplantation. <i>Comparative Medicine</i> , 2006, 56, 209-14.	1.0	8
173	Lymphoproliferative disorders: prospects for gene therapy. <i>Pathology</i> , 2005, 37, 523-533.	0.6	4
174	Neutral amino acid transport in epithelial cells and its malfunction in Hartnup disorder. <i>Biochemical Society Transactions</i> , 2005, 33, 233-236.	3.4	41
175	Characterization of mouse amino acid transporter BOAT1 (slc6a19). <i>Biochemical Journal</i> , 2005, 389, 745-751.	3.7	137
176	Interleukin-10 regulates arterial pressure in early primate pregnancy. <i>Cytokine</i> , 2005, 29, 176-185.	3.2	38
177	PCR-based expression analysis and identification of microRNAs. <i>Journal of RNAi and Gene Silencing</i> , 2005, 1, 44-9.	1.2	17
178	Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. <i>Nature Genetics</i> , 2004, 36, 1003-1007.	21.4	241
179	Synthetic elastin hydrogels derived from massive elastic assemblies of self-organized human protein monomers. <i>Biomaterials</i> , 2004, 25, 4921-4927.	11.4	227
180	Stem cell therapy of the liver? Fusion or fiction?. <i>Liver Transplantation</i> , 2004, 10, 471-479.	2.4	47

#	ARTICLE	IF	CITATIONS
181	Biodistribution of the RD114/mammalian type D retrovirus receptor, RDR. Journal of Gene Medicine, 2004, 6, 249-259.	2.8	37
182	The Biology of CD45 and its Use as a Therapeutic Target. Leukemia and Lymphoma, 2004, 45, 229-236.	1.3	55
183	Dynamic association of the mammalian insulator protein CTCF with centrosomes and the midbody. Experimental Cell Research, 2004, 294, 86-93.	2.6	36
184	Molecular Cloning of Mouse Amino Acid Transport System B0, a Neutral Amino Acid Transporter Related to Hartnup Disorder. Journal of Biological Chemistry, 2004, 279, 24467-24476.	3.4	222
185	Sensitive Flow Cytometric Analysis Reveals a Novel Type of Parent-of-Origin Effect in the Mouse Genome. Current Biology, 2003, 13, 955-959.	3.9	36
186	A sensitive dual-fluorescence reporter system enables positive selection of ras suppressors by suppression of ras-induced apoptosis. Cancer Gene Therapy, 2003, 10, 745-754.	4.6	8
187	Transdifferentiation: an attractive concept in search of evidence. Pathology, 2003, 35, 5.	0.6	1
188	Transdifferentiation: an attractive concept in search of evidence. Pathology, 2003, 35, 5.	0.6	4
189	Rapid Screening for High-Titer Retroviral Packaging Cell Lines Using an <i>In Situ</i> Fluorescence Assay. Human Gene Therapy, 2002, 13, 1005-1013.	2.7	8
190	BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6806-6811.	7.1	319
191	Ex Vivo Selection for Oncoretrovirally Transduced Green Fluorescent Protein-Expressing CD34-Enriched Cells Increases Short-Term Engraftment of Transduced Cells in Baboons. Human Gene Therapy, 2002, 13, 891-899.	2.7	13
192	Hartnup disorder: Polymorphisms identified in the neutral amino acid transporter SLC1A5. Journal of Inherited Metabolic Disease, 2002, 25, 437-448.	3.6	15
193	Is inheritable genetic modification the new dividing line?. , 2001, , 1-16.		1
194	The science of inheritable genetic modification. , 2001, , 17-34.		1
195	Sustained multilineage gene persistence and expression in dogs transplanted with CD34+ marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. Blood, 2001, 98, 2065-2070.	1.4	75
196	ZNF265 is a novel spliceosomal protein able to induce alternative splicing. Journal of Cell Biology, 2001, 154, 25-32.	5.2	64
197	Precise gene localization by phenotypic assay of radiation hybrid cells. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 7388-7392.	7.1	9
198	A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: Possible role in G protein-coupled signal transduction. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 1385-1390.	7.1	210

#	ARTICLE	IF	CITATIONS
199	The RD114/simian type D retrovirus receptor is a neutral amino acid transporter. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 2129-2134.	7.1	212
200	Reporters of Gene Expression: Autofluorescent Proteins. Current Protocols in Cytometry, 1999, 7, Unit 9.12.	3.7	2
201	Molecules in focus The thrombopoietic factor, Mpl-ligand. International Journal of Biochemistry and Cell Biology, 1998, 30, 657-660.	2.8	1
202	Improved Gene Transfer Into Baboon Marrow Repopulating Cells Using Recombinant Human Fibronectin Fragment CH-296 in Combination With Interleukin-6, Stem Cell Factor, FLT-3 Ligand, and Megakaryocyte Growth and Development Factor. Blood, 1998, 92, 1878-1886.	1.4	254
203	Retrovirus Packaging Cells Expressing the <i>Mus dunni</i> Endogenous Virus Envelope Facilitate Transduction of CHO and Primary Hematopoietic Cells. Journal of Virology, 1998, 72, 10242-10245.	3.4	11
204	Improved Gene Transfer Into Baboon Marrow Repopulating Cells Using Recombinant Human Fibronectin Fragment CH-296 in Combination With Interleukin-6, Stem Cell Factor, FLT-3 Ligand, and Megakaryocyte Growth and Development Factor. Blood, 1998, 92, 1878-1886.	1.4	54
205	Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice. Leukemia, 1997, 11, 732-742.	7.2	9
206	Mpl Ligand (MGDF) Alone and in Combination with Stem Cell Factor (SCF) Promotes Proliferation and Survival of Human Megakaryocyte, Erythroid and Granulocyte/Macrophage Progenitors. Stem Cells, 1997, 15, 33-42.	3.2	39
207	Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF. British Journal of Haematology, 1997, 97, 871-880.	2.5	63
208	Cytokine Receptor Expression on Hematopoietic Stem and Progenitor Cells. Blood, 1997, 89, 65-71.	1.4	14
209	Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet, The, 1996, 348, 1279-1281.	13.7	216
210	Activation of the Mitogen-Activated Protein Kinase Pathway Induces Transcription of the <i>PAC-1</i> Phosphatase Gene. Molecular and Cellular Biology, 1996, 16, 2913-2921.	2.3	74
211	Thymoma and agranulocytosis: two case reports and literature review. British Journal of Haematology, 1996, 95, 52-56.	2.5	46
212	Attenuated platelet sensitivity to collagen in patients with neurofibromatosis type 1. British Journal of Haematology, 1995, 89, 582-588.	2.5	20
213	Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome. Medical Journal of Australia, 1992, 157, 192-193.	1.7	24